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Abstract
Background
In 2011, migrants accounted for 47% of newly diagnosed cases of HIV infection in
France, including 70% from Sub-Saharan Africa. These populations meet with specific
obstacles leading to late diagnosis and access to medical and social care. Reducing
these delays has a proven benefit to patients’ health and contributes to a better con-
trol of the epidemic by preventing secondary infections.
Methods
The objective of this study is to assess the cost-effectiveness impact of an early access
to care (ATC) for migrant people living with HIV (PLHIV) in France. The model
compares “early” vs. “late” ATC for migrant PLHIV in France, defined by an entry
into care with a CD4 cell count of 350 and 100/mm3 respectively, and integrate the
positive externality of treatment on prevention. To evaluate the cost-effectiveness of
“early” ATC, incidence and hidden prevalence among migrants in France were esti-
mated.
Findings
Early ATC strategy proved cost-saving, or cost-effective in the worst case scenario. In
the most favorable scenario, early ATC generated an average net saving of e198,000 per
patient, and prevented 0·542 secondary infection. In the worst case scenario, early ATC
strategy generated an average cost of e28,000, a cost-effectiveness ratio of e133,000
per averted infection and prevented 0·211 secondary infection.
Interpretation
In addition to individual health benefit, improving early ATC for migrant PLHIV
proves an efficient strategy in terms of public health and economics. These results
stress out the benefit of ensuring ATC for all individuals living with HIV in France.
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1 Introduction
The main benefit associated with early treatment of HIV is medical. An early care trans-
lates into significant health gains for patients whose life expectancy and quality of life in-
crease. Early treatment of HIV infection also has a double benefit from the economic and
public health point of view.
In 2011, the HPTN 052 trial’s results proved a 96% reduction in the number of new
infections among discordant couples when the infected partner was under ARV treatment.1
Detection and early treatment of HIV patients would thus avoid secondary infections that
would be associated with future costs of care. This collective benefit, or positive externality
of treatment, is likely to significantly alter the traditional framework of cost-benefit analysis.
On the top of the health benefit for those treated, early treatment of people infected with
HIV may not only be cost-effective but also cost-saving.
In France, migrant populations are considered as a risk group for HIV. Indeed, 34,500
migrants were considered to be infected with HIV in 2010 and people from sub-Saharan
Africa represent a share of nearly 40% in the new discoveries of HIV since 2003 in France.2,3
Unlike others risk groups such as MSMs or IDUs, migrant populations are characterized by
a significant delay in screening. According to the French Hospital Database on HIV, almost
50% of migrants diagnosed in France during 2011 had CD4 cell count levels lower than 350.
Given these data, the study of the benefits associated with earlier entry into care for the
migrant population in France is particularly relevant, especially in the light of the preventive
effect of ARVs provided by the results of HPTN 052 trial.
This article assess the cost-effectiveness impact of an early access to care (ATC) for
migrant people living with HIV (PLHIV) in France. The model integrates the positive
externality of ARV treatments on prevention of secondary infections. Moreover, existing
estimates of incidence and size of hidden prevalence among migrants in France were cor-
rected to take into account the specificity of the epidemics among this population which is
partly imported. The main results of this study suggest that an earlier entry to care for
migrant would constitute a cost-saving or at least a cost-effective intervention even in the
scenarios implying the most unfavorable hypothesis. Indeed, even if earlier treatment initi-
ation increases life expectancy and the lifetime total cost of care, the decrease in secondary
1
infections made possible by this intervention compensate this overspending by suppressing
future costs of care.
This article proceeds as follows. Section 2 describes the model used in the analysis,
section 3 looks for the values of model parameters, section 4 presents the results and section
5 evaluates their robustness. The last section concludes.
2 Modeling of intervention
2.1 Secondary infections
The model compares “early” (1) and “late” (2) ATC for migrants living with HIV in
France. “Early” ATC is defined as entry into care at time t1 after infection, with a CD4
cell count of 350, whereas “late” ATC is defined as entry into care at time t2 with CD4
cell count of 100/mm3. The average number of secondary infections caused by a person
infected with HIV throughout his/her life is denoted by R0. It can be decomposed by year
as R0 =
∑
T
t=1
rt0, where r
t
0 is the average annual number of secondary infections caused by
an HIV-infected individual in year t after infection, and T is her remaining life expectancy.
Both T and rt0 depend on the treatment received by the individual. We denote by r¯0 the
value of rt0 in the first year after infection. Due to the phase of high viral load during
seroconversion, this value is larger than r0, the value of r
t
0 after this early stage. Finally, this
value is changed into αr0 when the individual is under treatment.
One key parameter in our analysis is α, which results from two effects. The first is the
reduction in infectivity induced by treatment. The second is the impact that diagnosis may
have on risk behaviors. When the net effect is a reduction in disease transmission we have
α < 1.
Life expectancy is affected by the timing of treatment initiation: we denote by T1 the
value of T for individuals with early ATC, and by T2 < T1 the corresponding value with late
ATC.
Under these notations, the total number of secondary infections of an HIV-infected pa-
tient who benefits from a treatment at date ti is equal to:
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R0 = r¯0 +
ti∑
t=2
r0 +
Ti∑
t=ti+1
αr0.
The number of secondary infections avoided thanks to the early treatment strategy is
therefore equal to:
R
2
0 −R
1
0 = r¯0 + (t2 − 1)r0 + α(T2 − t2)r0
− [r¯0 + (t1 − 1)r0 + α(T1 − t1)r0]
= r0[(1− α)(t2 − t1)− α(T1 − T2)]
The first term represents the decrease in secondary infections thanks to the earlier treat-
ment initiation and the second term stands for the increase in secondary infections due to a
prolonged life expectancy for early treated patients.
Figure 1 describes early and late ATC strategies:
Figure 1: Comparison of early and late ATC
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2.2 Costs
For each strategy, we compute TCi, the total treatment costs under strategy i = 1 (early
treatment) or i = 2 (late treatment). This total cost is defined as the lifelong cost of care
once the patient is diagnosed Ci, plus the cost of secondary infections. By convention, we
value this cost at C1, which corresponds to the assumption that all individuals who are
secondarily infected will benefit from early treatment. Under this assumption, we have that
TCi = Ci +R
i
0C1.
Notice that early treatment strategy is cost-saving if TC1 < TC2, i.e. if:
(C1 − C2) < C1(R
1
0 −R
2
0)
< C1r0[(1− α)(t2 − t1)− α(T1 − T2)]
The cost-saving potential of the early treatment strategy depends on the tradeoff between
the savings generated by the decrease in secondary infections thanks to early treatment and
the extra cost associated with the increase in life expectancy for early treated patients.
3 Parameters value
3.1 Treatment timing and cost parameters
Existing literature on treatment timing and costs in the era of HIV/AIDS provides confi-
dent estimates for these parameters which allows us to build a central scenario. The impact
of these parameters value on final results will be tested in robustness analysis in section 5.
Annual costs of care for early treated and late treated patients are provided by an article of
Sloan, Champenois, Choisy and al. in which the authors simulate the evolution of two cohorts
of French patients based on their CD4 level at treatment initiation.4 Treatment timings
are suggested by Lodi, Philips, Touloumi et al. who estimates the median time between
seroconversion and CD4 cell counts of 200, 350 and 500 from the CASCADE data gathering
4
25 patients’ cohorts in Europe, Australia, Canada and sub-Saharan Africa.5 Finally, life
expectancy under treatment for early and late presenters is based on the results of the ART
Cohort Collaboration which synthesizes data on 14 cohorts of patients in North America
and Europe.6 Table 1 summarizes the parameters values :
Definition Value Value
(early treatment) (late treatment)
Ci Lifelong cost of care 686,426 513,200
ti Treatment start date 4 9
Ti Death date 38 32.8
Table 1: Treatment timing and cost parameters
3.2 Value of α and r0
Existing literature does not provide reference values for α and r0. Based on available in-
formation we therefore estimate plausible values for these parameters allowing us to simulate
different scenarios of intervention.
3.2.1 Value of α
The parameter α reflects the change in the annual number of secondary infections for
HIV positive migrants who are diagnosed, and its value depends on both the reduction
of infectivity under treatment and the evolution of preventive behaviors once patients are
diagnosed.
The decline in infectivity of patients receiving ARV treatment is related to the decrease
in viral load induced by the treatment and depends in part on patients’ adherence. The
decrease in infectivity for ARV patients is probably less than the 96% measured in the
HPTN 052 trial where the conditions of care and adherence’s monitoring were optimal.1
Observational cohort studies may allow us to get a better approximation for the decline of
infectivity under treatment in real life conditions. Three meta-analyzes provide more or less
optimistic results ranging from 92% to only 84%.7-9 Following these results, we assume a
90% reduction in infectivity for migrants under treatment in France.
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Two scenarios for the evolution of preventive behaviors after diagnosis are explored.
Following Marks, Crepaz, Senterfitt and Janssen, the scenario assumes a favorable change in
preventive behaviors by a 53% decline in the share of unprotected sex acts after diagnosis.10
In the pessimist scenario, we assume no change in sexual behaviors following diagnosis.
In short, when sexual behaviors are unchanged, the value of α is equal to 0·1, whereas
if we assume a 53% reduction in unprotected sexual acts after diagnosis, the value of α
decreases to 0·047.
3.2.2 Value of r0
No estimation of r0 is available for migrant populations in France. We therefore approx-
imate it by calculating the annual number of new transmissions in the migrant category
which is due to undiagnosed migrants and by dividing it by the total number of undiagnosed
migrants in France. Therefore three types of data are required: the number of undiagnosed
migrants present in France (1), the number of new infections among migrants in France each
year (2) and the share of these new infections caused by undiagnosed HIV infected migrants
(3). Available estimations of incidence and hidden prevalence among migrants in France
are based on back-calculation from mandatory reportings of HIV cases. Such estimations
are marked with uncertainty and raise specific difficulties in the migrant population where a
significant part of infections is imported from home countries of migrants. Thus, in the rest
of the section we try to adjust existing estimates for this bias.
Ndawinz, Costagliola and Supervie estimated that 2469 new transmissions occurred
among migrants in 2007.11 However, a significant share of these new infections may have
occurred in the birth country of migrants. An assumption has thus to be made regarding
the share of these new transmissions that took place in France. Among migrants interviewed
in the VESPA 2 survey conducted in 2011 among PLHIV in France by the ANRS, 32·9% de-
clared a contamination in France. Assuming a relative stability in incidence for the migrant
category since 2007, and given the share of infections among migrants occurring in France,
the number of new infections among migrants in France each year is assumed to be 812.
Based on ANRS estimates for 2010, 9500 undiagnosed migrants live in France. This
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estimation relies on incidence estimates in the migrant population obtained through back-
calculation. It therefore tends to overestimate the actual size of the hidden epidemics among
migrants in France. As some migrants are infected ante-migration in their home country,
ANRS estimates might include by anticipation migrants infected in their country of origin
but not yet arrived in France.2,3 The estimated 9500 migrants with undiagnosed HIV can
be divided into three categories: migrants infected in France (1), migrants infected abroad
but present on the French territory (2) and migrants infected abroad but not yet arrived
in France (3). According to previous estimates for the share of new infections occurring in
France we consider that the first group represents 32·9% of undiagnosed migrants, that is to
say 3125 undiagnosed migrants infected in France. Groups (2) and (3) should therefore be
constituted by 67·1% of the 9500 undiagnosed migrants (6375 migrants). The distribution
of migrants between these two categories will depend on several factors including the time
between infection and migration and the timing of diagnosis after arrival in France. One way
to approximate the distribution of undiagnosed migrants infected abroad between categories
(2) and (3) (present or not present in France) is to rely on the share of the total undiagnosed
time spent in France or in the country of origin for migrants infected abroad.
The VESPA2 survey provides data on year of arrival in France, year of diagnosis, year of
first medical examination related to HIV and CD4 level at this time for all migrants declaring
a contamination in their country of origin. From these data, age of infection at first exami-
nation can be estimated based on data of Lodi, Philips, Touloumi et al.5 This allows in turn
to determine a probable date of infection for each of these migrants. From the supposed year
of infection and the year of arrival in France it is then possible to calculate the total time
spent undiagnosed and the share of that time spent in France or in the country of origin.
From calculations based on VESPA2 data we estimated a share of undiagnosed time spent in
France ranging from 23·43% ([18·58, 28·28]) to 47·24% ([40·98, 53·49]) for migrants infected
in their country of origin. If we use these estimates as a proxy for the distribution between
groups (2) and (3) we can consider that 23·43 to 47·24% of the 6375 undiagnosed migrants
infected abroad are actually in France (1494 to 3012 migrants infected abroad but already
in France). Summing up these estimates to the number of migrants infected in France, there
would be between 4619 and 6137 undiagnosed HIV positive migrants on the French territory.
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The share of HIV infections attributable to undiagnosed HIV migrants is calculated fol-
lowing the calculation method developed by Marks, Crepaz and Janssen.12 As said above for
the value of α, two scenarios are considered for the evolution of risk behaviors following the
HIV diagnosis.
Table 2 summarizes the possible values for r0 depending on hypothesis on the size of
hidden epidemic among migrants and the evolution of risk behaviors following diagnosis:
❤
❤
❤
❤
❤
❤
❤
❤
❤
❤
❤
❤
❤
❤
❤
❤
❤
❤
❤
❤
❤
Preventive behaviors
Hidden epidemics
Low High
Optimist 0·091 0·0778
Pessimist 0·0589 0·0531
Table 2: Possible values of r0
4 Results
Four scenarios are considered in the analysis depending on hypothesis on the size of the
hidden epidemics and the evolution of preventive behaviors following diagnosis. Table 3
summarizes the results of scenarios analysis.
Evolution of preventive behaviors Optimist Pessimist
Hidden prevalence Low High Low High
Scenario 1 Scenario 2 Scenario 3 Scenario 4
r0 0·091 0·0778 0·0589 0·0531
α 0·047 0·047 0·1 0·1
Net cost of early ATC -109,152 -68,192 12,313 28,158
Averted infections (AI) for early ATC 0·4114 0·3517 0·2344 0·2113
Cost per AI for early ATC Cost-saving Cost-saving 52,532 133,237
Table 3: Results of scenarios analysis
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Results show that early treatment for HIV-infected migrants in France is a cost-saving
intervention when risk behaviors decrease after diagnosis. In the most favorable case (sce-
nario 1), early ATC generates an average net saving of e109,000 per patient and prevents
0·41 secondary infection. When no change in risk behavior is assumed after diagnosis, the
early ATC strategy allows for a reduction in the number of secondary infections but gener-
ates a net cost compared to the late treatment strategy. In the worst case scenario (scenario
4), early ATC prevents 0·2 secondary infection but generates an additional cost of e28,000,
which leads to a cost-effectiveness ratio of e133,000 per averted infection.
5 Sensitivity analysis
Table 4 presents cost-effectiveness ratios resulting from adverse changes in t parameters.
The first situation assumes that the treatment delay for late presenters (t2 − t1) is reduced
from 5 to 4 years. The second one runs the simulation when life expectancy for early
presenters (T1 − t1) increases from 32 to 36 years, and the third one when life expectancy
for late presenters (T2 − t2) decreases from 23.8 to 22 years. The fourth simulation assumes
that instead of C1, the benefit of preventing a secondary infection is reduced to C2. Finally,
the last simulation investigates the case where late presenters start treatment later at a CD4
cell count of 200 instead of 350.
Cost per averted infection in e
Scenario 1 Scenario 2 Scenario 3 Scenario 4
t2 − t1 = 4 Cost-saving Cost-saving 268,450 372,750
T1 − t1=36 (C1=726 804) Cost-saving Cost-saving 232,603 337,393
T2 − t2= 22 (C2=474 387) Cost-saving Cost-saving 260,939 364,420
Value of infection averted = C2 Cost-saving Cost-saving 225,750 306,460
Late ATC at 200 CD4 cell count Cost-saving Cost-saving 102,841 189,051
Table 4: Results of sensitivity analysis
Early ATC remains cost saving in scenarios 1 and 2. Early initiation strategies thus
remain cost-saving when risk behaviors decrease after diagnosis. Under scenarios 3 and
4, which are more pessimistic in terms of sexual behavior evolution, the cost per averted
9
infection ranges from 104 keto 372 ke.
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6 Conclusion
When early and late treatment are respectively defined as entry into care at 350 and 100
CD4, reducing the time delay between infection screening and treatment initiation appears
to be a cost-saving intervention or at least cost-effective, even in the worst scenarios. If a
decrease in risk behaviors is assumed after diagnosis, these results remain robust when late
treatment is defined as an entry into care at 200 CD4, or when more pessimistic values of
the key model parameters are assumed.
Beyond the medical benefits for treated patients, earlier diagnosis and treatment for HIV-
positive migrants is also desirable from an economic point of view. Even if earlier treatment
increases life expectancy and therefore the lifetime cost of care of HIV patients, the decrease
in the number of secondary infections associated with such an intervention can offset this
extra cost by avoiding expenditures in the future.
The main contributions of this article are twofold. This article is the first attempt to
integrate the preventive effect of ARV treatments in cost-effectiveness analysis of treatments
for the migrant population in France. Moreover, existing estimates of incidence and size
of hidden prevalence among migrants in France were corrected to take into account the
specificity of the epidemics among this population which is partly imported.
The main limitation of this evaluation is related to the static nature of the model studied.
A static model can only take into account infections averted in the first stage while a dynamic
model could highlight the cumulative process of avoided secondary infections. In the real
world, people whose infection is avoided thanks to the intervention would also have infected
other people if they had been infected. The results from the static model therefore tend to
underestimate both the number of infections averted and the savings due to earlier treatment
of HIV-positive migrants.
The model studied in this paper is simple. Its main benefit is to make explicit all
the assumptions under which costs and impact of different strategies are simulated. The
simulations shows that earlier treatment initiation for migrants should be promoted, from
both economic and public health points of view, even though a part of the benefits associated
with this type of intervention cannot be directly taken into account. Thus, it seems that any
intervention promoting greater use of screening and better access to care for HIV-positive
11
migrants should be recommended.
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